The presentation entitled “Delivering Value for Patients Through Nanoforming in Plasma-Derived Therapies” will focus on two proof-of-concept studies conducted using Nanoform technology to enhance subcutaneous and inhaled biologic treatments.

The first study evaluated the suitability of nanoformed high-concentration biologics formulations for subcutaneous delivery. Protein concentrations above 200 mg/mL often exceed the acceptable viscosity limit for subcutaneous injection. The findings, supported by syringeability studies suggest that Nanoform’s patented biologics platform can achieve high protein concentrations in suspension formulations suitable for subcutaneous delivery.

The second non-clinical proof-of-concept study investigated nanoformed Alpha-1 antitrypsin (A1AT) in the treatment of Alpha-1 antitrypsin (AAT) deficiency, a genetic disorder linked to lung diseases such as emphysema. Results showed that the nanoformed therapy showed promise as a targeted therapeutic approach. AAT deficiency is typically treated with weekly IV infusions of plasma-derived AAT, which is often inconvenient for patients. The study evaluated dry powder inhalation as an alternative route of administration for AAT replacement therapy, leveraging Nanoform’s novel solidification platform.

The 15th American Drug Delivery & Formulation Summit runs from September 15-16, 2025 (American Drug Delivery & Formulation Summit 2025) at The Westin Copley Place, Boston, Mass.

Nanoform also announced that Dr. Christopher P. Worrall, Ph.D., Vice President of Business Development, US, Nanoform, will present key case-study findings during a Solution Spotlight session at DDF.

His presentation, titled “Highly Concentrated mAb SubQ Formulations Using Nanoformed Particles: Trastuzumab,” will take place in Room 1 on Monday, September 15, from 12:15 to 12:45 p.m. EST, and will highlight the development of a highly concentrated, non-aqueous subcutaneous formulation of trastuzumab developed using Nanoform’s Bio platform.

For more information on the summit visit: nanoform.com/events. To arrange a meeting with Dr. Worrall at the DDF event, contact Christian Jones, Chief Commercial Officer, Nanoform, christian.jones@nanoform.com.

For further information, please contact:

Christian Jones, Chief Commercial Officer
Christian.jones@nanoform.com
+44 (0)7804 474 771

Henri von Haartman, Director of Investor Relations
hvh@nanoform.com
+46 (0)7686 650 11

About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@carnegie.se. For more information, please visit www.nanoform.com.

Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words “may”, “will”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend”, believe”, “estimate”, “predict”, “project”, “potential”, “continue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform’s business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2024 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.